- HealthTech
- Tuesday, 09 Jun 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
The new clinical manufacturing facility will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
Related Industry Updates
Accela Cloud Solutions Enable U.S. Cities and Counties to Rapidly Adapt to COVID-19 Crisis
Jun 12, 2020
Burn Dressing Market 2021 Size, Share, Growth, Trends, Analysis, Revenue, Competitive Landscape, Forecast Report 2021-2027
Mar 02, 2021
Silent Heart attack Market To Witness Stunning Growth To Generate Massive Revenue Till 2027 | AstraZeneca plc, Bionet, Koninklijke Philips N.V., Merck & Co., Midmark Corporation & More
May 06, 2021
Corporate Wellness Market Report Covers Detailed Industry Scope, Future Scenario and Elaborates Outlook to 2027
Jun 08, 2020
Covid-19 Impact on North America Starch Softgel Capsules Market 2020 Segmentation, Demand, Growth, Trend, Opportunity and Forecast to 2027
Aug 28, 2020
New report: Anticoagulant Reversal Drugs Market opportunities and forecast assessment, 2020 to 2027
Mar 25, 2021
Pharmaceutical Packaging Market Demand Would Increase Rapidly By 2027
Jan 04, 2021
Follow us on
